Evidence map›Paper›PMID 37733693›Full record

ArticlePloS one2023

Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol.

Sri Mahavir Agarwal, Joel Dissanayake, Ofer Agid, Christopher Bowie, Noah Brierley, Araba Chintoh, Vincenzo De Luca, Andreea Diaconescu, Philip Gerretsen, Ariel Graff-Guerrero and 26 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Sri Mahavir AgarwalSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0002-2705-5146
Joel DissanayakeSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Ofer AgidSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Christopher BowieSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Noah BrierleySchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Araba ChintohSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Vincenzo De LucaSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Andreea DiaconescuSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Philip GerretsenSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Ariel Graff-GuerreroSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Colin HawcoSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Yarissa HermanSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Sean HillSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0001-8055-860X
Kathryn HumSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Muhammad Omair HusainSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
James L KennedySchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Michael KiangSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Sean KiddSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0002-2435-786X
Nicole KozloffSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0003-1389-1351
Marta MaslejSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Daniel J MuellerSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Farooq NaeemSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Nicholas NeufeldSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Gary RemingtonSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Martin RotenbergSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Peter SelbySchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0001-5401-2996
Ishraq SiddiquiSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Kate Szacun-ShimizuSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0002-2897-2122
Arun K TiwariSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Shanthos ThirunavukkarasuSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Wei WangSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Joanna YuSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Clement C ZaiSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Robert ZipurskySchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
Margaret HahnSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
George FoussiasSchizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.ORCID 0000-0001-6220-519X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia spectrum disorders (SSDs) are associated with significant functional impairments, disability, and low rates of personal recovery, along with tremendous economic costs linked primarily to lost productivity and premature mortality. Efforts to delineate the contributors to disability in SSDs have highlighted prominent roles for a diverse range of symptoms, physical health conditions, substance use disorders, neurobiological changes, and social factors. These findings have provided valuable advances in knowledge and helped define broad patterns of illness and outcomes across SSDs. Unsurprisingly, there have also been conflicting findings for many of these determinants that reflect the heterogeneous population of individuals with SSDs and the challenges of conceptualizing and treating SSDs as a unitary categorical construct. Presently it is not possible to identify the functional course on an individual level that would enable a personalized approach to treatment to alter the individual's functional trajectory and mitigate the ensuing disability they would otherwise experience. To address this ongoing challenge, this study aims to conduct a longitudinal multimodal investigation of a large cohort of individuals with SSDs in order to establish discrete trajectories of personal recovery, disability, and community functioning, as well as the antecedents and predictors of these trajectories. This investigation will also provide the foundation for the co-design and testing of personalized interventions that alter these functional trajectories and improve outcomes for people with SSDs.

Indexed as

SchizophreniaHumansKnowledgeMortality, PrematureNeurobiologyPhysical Examination

Identifiers

PMID37733693
PMCPMC10513234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.